Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/29/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK
6. S
7. GAP
8. DG
9. ULTA
10. NVDA

Go back to Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
(NASDAQ: NVCR) Delayed: 17.82 -0.17 (0.94%)
Previous Close $17.99    52 Week High $28.95 
Open $17.99    52 Week Low $5.95 
Day High $18.16    P/E N/A 
Day Low $17.42    EPS $0.00 
Volume 855,584